ClinicalTrials.gg
CompletedNCT00493649Updated Nov 3, 2016Results posted

Adj TC + Herceptin Early Stage Breast Cancer

A Phase 2 interventional study of Taxotere and Cytoxan in Breast Cancer, sponsored by US Oncology Research. Completed at 69 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-11-03.

Sponsored by US Oncology Research (part of Sarah Cannon Research Institute) · Phase 2, Interventional, and Treatment

How we know · 8 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
493
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 264 studies testing docetaxel in Breast Neoplasms — 19 open to participants now, 26 under way, 8 of them phase 3. Docetaxel · Breast Neoplasms.

Enrollment
30th of 248
493 · median 68
Started
2007
with 18 others
Phase 2
157 of 264
11 open now
Registered
133rd of 264
by date

Among the 264 studies testing docetaxel in Breast Neoplasms, this one is the 30th largest by enrollment of the 248 interventional ones that give a count, is one of 19 that started in 2007, is one of 157 in phase 2, and was the 133rd registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 264 studies testing docetaxel in Breast Neoplasms are open now, in 9 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 264 studies testing docetaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this research study is to find out what effects (good and bad) docetaxel/cyclophosphamide (brand names: Taxotere and Cytoxan, or TC) plus trastuzumab (brand name: Herceptin, or H) has HER2+ breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A woman will be eligible for inclusion in this study if she meets all of the following criteria:

  • Has + (IHC staining of 3+ [uniform, intense membrane staining of >30% of invasive tumor cells], or a FISH result of .6 HER2 gene copies per nucleus or a FISH ratio [HER2 gene signals to chromosome 17 signals] of >2.2; patients with equivocal FISH ratio results 1.8-2.2 are also eligible if 3+ IHC) (Appendix IX); Stage I, IIA, IIB, or IIIA T1-3N1-3M0 disease. At the discretion of the Treating Physician, patients with 4+ nodes with other factors such as patient choice, older age, preexisting cardiac disease with normal or ECHO may be enrolled into a separate subgroup.
  • Has operable, confirmed, invasive carcinoma of the breast.
  • Has known ER and PR status
  • Has adequate tumor specimen available for FISH analysis of TOP2A status (See Appendix VII)
  • Has had no prior chemotherapy unless it was given >5 years ago for breast cancer or other cancer
  • Has an Performance Status (PS) 0-1
  • Age >18 to \<70 years old.
  • Has laboratory values of: See protocol for specific details
  • Has (AST) or alanine aminotransferase (ALT) and alkaline phosphatase (ALP) within the ranges shown below. In determining eligibility the more abnormal of the 2 values (AST or ALT) should be used. See protocol for specific details
  • Has complete surgical resection of the primary breast tumor: either lumpectomy or mastectomy with sentinel lymph node or axillary dissection.
  • It has been \<84 days since the date of definitive surgery, and there is adequate wound healing as determined by the Treating Physician
  • Has no evidence of disease by physical examination and x-ray; appropriate scans as needed by each individual patient (eg, bone scan; abdominal, chest CT; PET or PET/CT; ultrasound; or MRI should indicate no evidence of metastatic disease.
  • Has normal cardiac function as evidenced by a LVEF >50%, but must be within normal limits (WNL) by institutional standard, as determined by multiple gated acquisition (MUGA) scan. An echocardiogram (ECHO). The same modality must be used throughout the study to evaluate LVEF. Ejection fraction (EF) as determined by ECHO must be WNL by institutional standard.
  • Has a negative serum pregnancy test within 7 calendar days prior to registration (female patients of [not surgically sterilized and between menarche and 1 year ]).
  • If fertile, patient has agreed to use an acceptable method of (barrier contraceptive) to avoid pregnancy for the duration of the study and for a period of 3 months thereafter
  • Has signed a Patient Form
  • Has signed a Patient Authorization Form

Exclusion criteria

Exclusion Criteria:

A woman will be excluded from this study if she meets any of the following criteria:

  • Has any evidence of disease following complete surgical resection of the primary tumor and workup
  • Has Stage IIIB breast cancer (T4 disease; ie, patients with fixed tumors, peau d'orange skin changes, skin ulcerations, or inflammatory changes).
  • Has Stage IV breast cancer (M1 disease on TNM staging system)
  • Had prior chemotherapy for breast cancer or other cancer within the last 5 years (no chemotherapy in this study is permitted)
  • Has a history of severe reaction to drugs formulated with polysorbate 80
  • Has had a myocardial infarction (MI) within 6 months of trial enrollment, or has (NYHA) Class II or greater heart failure (see Appendix III), uncontrolled angina, severe uncontrolled ventricular arrhythmias, pericardial disease, or electrocardiographic evidence of acute ischemic changes
  • Has abnormal baseline (or ECHO) (\<50%, or less than institutional LLN)
  • Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy. Adjuvant hormonal therapy, if needed, may be given during radiation therapy and during treatment with trastuzumab after completion of chemotherapy.
  • Is receiving concurrent therapy or has received such therapy within the past 30 calendar days
  • Has peripheral neuropathy >Grade 1
  • Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious viral (including clinically defined AIDS), bacterial or fungal infection; or history of uncontrolled seizures, or diabetes, or CNS disorders deemed by the Treating Physician to be clinically significant, precluding
  • Has active or with abnormal liver function tests (LFTs) or is known to be positive
  • Has a history of other within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs
  • Is an obese patient to whom the Treating Physician would not be comfortable administering full doses of study drugs as calculated by the BSA. Obese patients will be treated based on actual body weight. Obese patients treated with full doses based on actual BSA are eligible
  • Is a pregnant or breastfeeding woman
  • Is deemed unable to comply with requirements of study
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    TC+H

    On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel (Taxotere) 75 mg/m2 IV (over 1 hour), plus cyclophosphamide (Cytoxan) 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab (Herceptin) 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter.

    Drug: Taxotere · Drug: Cytoxan · Drug: Herceptin

Interventions

  • DrugDocetaxelStudies of DocetaxelDocetaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.

    Also known as: docetaxel

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.

    Also known as: cyclophosphamide

  • DrugTrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.

    Also known as: trastuzumab

06

What researchers measure

Primary outcomes

  1. Disease-free Survival (DFS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.

    DFS was measured from the date of registration to either the date the patient was first recorded as having disease recurrence, or the date of death due to any causes before recurrence. If a patient had not recurred or died, DFS was censored at the date of last follow-up.

    Time frame: 2 years

Secondary outcomes

  1. Overall Survival (OS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.

    OS is measured from the date of registration to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

    Time frame: 2 years

  2. DFS by cMyc Expression in This Population of HER2+ ESBC Patients Treated With TC+H.

    DFS was measured from the date of registration to either the date the patient was first recorded as having disease recurrence, or the date of death due to any causes before recurrence. If a patient had not recurred or died, DFS was censored at the date of last follow-up.

    Time frame: 2 years

  3. OS by cMyc Expression in This Population of HER2+ ESBC Patients Treated With TC+H.

    OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

    Time frame: 2 years

07

Results

Posted Nov 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneTC+H
Started493
Completed411
Not completed82
Withdrew: Adverse event44
Withdrew: Patient request21
Withdrew: Investigator request2
Withdrew: Disease progression1
Withdrew: Lost to follow-up1
Withdrew: Other13

Outcome measures

PrimaryDisease-free Survival (DFS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.

DFS was measured from the date of registration to either the date the patient was first recorded as having disease recurrence, or the date of death due to any causes before recurrence. If a patient had not recurred or died, DFS was censored at the date of last follow-up.

Time frame:
2 years
Reported as:
Number · probability of disease-free survival
Disease-free Survival (DFS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.
probability of disease-free survivalTOP2A-amplified GroupTOP2A-nonamplified Group
Disease-free Survival (DFS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.0.978 (0.942 to 0.992)0.979 (0.949 to 0.991)
SecondaryOverall Survival (OS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.

OS is measured from the date of registration to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

Time frame:
2 years
Reported as:
Number · probability of overall survival
Overall Survival (OS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.
probability of overall survivalTOP2A-amplified GroupTOP2A-nonamplified Group
Overall Survival (OS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.0.995 (0.962 to 0.999)0.988 (0.962 to 0.996)
SecondaryDFS by cMyc Expression in This Population of HER2+ ESBC Patients Treated With TC+H.

DFS was measured from the date of registration to either the date the patient was first recorded as having disease recurrence, or the date of death due to any causes before recurrence. If a patient had not recurred or died, DFS was censored at the date of last follow-up.

Time frame:
2 years
Reported as:
Number · probability of disease-free survival
DFS by cMyc Expression in This Population of HER2+ ESBC Patients Treated With TC+H.
probability of disease-free survivalcMYC-amplified GroupcMYC-nonamplified Group
DFS by cMyc Expression in This Population of HER2+ ESBC Patients Treated With TC+H.0.968 (0.904 to 0.990)0.981 (0.958 to 0.991)
SecondaryOS by cMyc Expression in This Population of HER2+ ESBC Patients Treated With TC+H.

OS is measured from the date of randomization to the date of death for a dead patient. If a patient is still alive or is lost to follow up, the patient will be censored at the last contact date.

Time frame:
2 years
Reported as:
Number · probability of overall survival
OS by cMyc Expression in This Population of HER2+ ESBC Patients Treated With TC+H.
probability of overall survivalcMYC-amplified GroupcMYC-nonamplified Group
OS by cMyc Expression in This Population of HER2+ ESBC Patients Treated With TC+H.0.990 (0.930 to 0.999)0.991 (0.972 to 0.997)

Adverse events

Collected over During the whole treatment period, up to 30 days following last dose.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TC+H—51/486 (10.5%)481/486 (99%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventTC+H
FEBRILE NEUTROPENIAInfections and infestations22/486
DEHYDRATIONGastrointestinal disorders5/486
DIARRHEAGastrointestinal disorders5/486
FEVERGeneral disorders5/486
CELLULITISInfections and infestations4/486
NEUTROPENIABlood and lymphatic system disorders4/486
NAUSEAGastrointestinal disorders3/486
PNEUMONIARespiratory, thoracic and mediastinal disorders3/486
ABDOMINAL PAINGastrointestinal disorders2/486
SYNCOPENervous system disorders2/486
Most frequent other events
Showing 10 of 27
Most frequent other events
EventTC+H
ALOPECIASkin and subcutaneous tissue disorders339/486
FATIGUEGeneral disorders284/486
NEUTROPENIABlood and lymphatic system disorders247/486
NAUSEAGastrointestinal disorders216/486
DIARRHEAGastrointestinal disorders183/486
ANEMIABlood and lymphatic system disorders131/486
RASHSkin and subcutaneous tissue disorders104/486
NEUROPATHYNervous system disorders99/486
CONSTIPATIONGastrointestinal disorders90/486
MUCOSITISInfections and infestations89/486

Baseline characteristics

ITT population

Age, Continuous
Age, Continuous(years)TC+H
Mean55.1 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)TC+H
Female493
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)TC+H
Caucasian414
Black36
Hispanic27
Asian12
Indian1
Other3
Region of Enrollment
Region of Enrollment(participants)TC+H
United States493
08

Study locations

69 sites
  • Birmingham Hematology and Oncology
    Birmingham, Alabama 35205, United States
  • Hematology Oncology Associates
    Phoenix, Arizona 85012, United States
  • Northern AZ Hematology & Oncology Associates
    Sedona, Arizona 86336, United States
  • Arizona Oncology Associates DBA HOPE
    Tucson, Arizona 85704, United States
  • Rocky Mountain Cancer Center-Rose
    Denver, Colorado 80220, United States
  • Connecticut Oncology & Hematology, LLP
    Torrington, Connecticut 06790, United States
  • Florida Cancer Institute
    New Port richey, Florida 34655, United States
  • Ocala Oncology Center
    Ocala, Florida 34474, United States
  • Cancer Centers of Florida, P.A.
    Ocoee, Florida 34761, United States
  • Hematology Oncology Associates of IL
    Chicago, Illinois 60611, United States
  • Cancer Care & Hematology Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Central Indiana Cancer Centers
    Indianapolis, Indiana 46227, United States
  • Hope Center
    Terre Haute, Indiana 47802, United States
  • Kansas City Cancer Centers-Southwest
    Overland Park, Kansas 66210, United States
  • Maryland Oncology Hematology, P.A.
    Columbia, Maryland 21044, United States
  • Alliance Hematology Oncology P.A.
    Westminster, Maryland 21157, United States
  • Minnesota Oncology Hematology, P.A.
    Minneapolis, Minnesota 55404, United States
  • Missouri Cancer Associates
    Columbia, Missouri 65201, United States
  • Arch Medical Services, Inc.
    St. Louis, Missouri 63141, United States
  • Comprehensive Cancer Centers of Nevada
    Henderson, Nevada 89052, United States
  • Hematology-Oncology Associates of NNJ, P.A.
    Morristown, New Jersey 07960, United States
  • New Mexico Cancer Care Associates
    Santa Fe, New Mexico 87505, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12006, United States
  • Ruth Oratz MD
    New York, New York 10016, United States
  • Interlakes Oncology Hematology, PC
    Rochester, New York 14623, United States
  • Cancer Centers of North Carolina
    Raleigh, North Carolina 27607, United States
  • Greater Dayton Cancer Center
    Kettering, Ohio 45409, United States
  • Willamette Valley Cancer Center
    Eugene, Oregon 97401, United States
  • Medical Oncology Associates
    Kingston, Pennsylvania 18704, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29605, United States
  • Texas Cancer Center-Abilene (South)
    Abilene, Texas 79606, United States
  • Texas Oncology, P.A.-Amarillo
    Amarillo, Texas 79106, United States
  • Texas Cancer Center
    Arlington, Texas 76014, United States
  • Texas Oncology Cancer Center
    Austin, Texas 78731, United States
  • Mamie McFaddin Ward Cancer Center
    Beaumont, Texas 77702, United States
  • Texas Oncology, P.A.-Bedford
    Bedford, Texas 76022, United States
  • Texas Cancer Center at Medical City
    Dallas, Texas 75230, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75231, United States
  • Methodist Charlton Cancer Ctr.
    Dallas, Texas 75237, United States
  • Texas Oncology, P.A.
    Dallas, Texas 75246, United States
  • Texas Cancer Center
    Denton, Texas 76210, United States
  • El Paso Cancer Treatment Ctr
    EL Paso, Texas 79915, United States
  • Texas Oncology, P.A.
    Fort Worth, Texas 76104, United States
  • Texas Oncology, P.A.
    Garland, Texas 75042, United States
  • Texas Oncology, P.A.
    Houston, Texas 77024, United States
  • Lake Vista Cancer Center
    Lewisville, Texas 75067, United States
  • Longview Cancer Center
    Longview, Texas 75601, United States
  • South Texas Cancer Center-McAllen
    McAllen, Texas 78503, United States
  • Texas Cancer Center of Mesquite
    Mesquite, Texas 75150, United States
  • Allison Cancer Center
    Midland, Texas 79701, United States
  • Texas Oncology-Odessa
    Odessa, Texas 79761, United States
  • Paris Regional Cancer Center
    Paris, Texas 75460, United States
  • San Antonio Tumor and Blood Clinic
    San Antonio, Texas 78217, United States
  • HOAST-Medical Dr.
    San Antonio, Texas 78229, United States
  • Texas Cancer Center-Sherman
    Sherman, Texas 75090, United States
  • Texas Oncology Cancer Center-Sugar Land
    Sugar Land, Texas 77479, United States
  • Tyler Cancer Center
    Tyler, Texas 75702, United States
  • Texas Oncology Cancer Care and Research
    Waco, Texas 76712, United States
  • Texas Oncology PA
    Webster, Texas 77598, United States
  • Texoma Cancer Center
    Wichita Falls, Texas 76310, United States
  • Fairfax Northern VA Hem-Onc PC
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates
    Norfolk, Virginia 23502, United States
  • Onc and Hem Associates of SW VA, Inc.
    Salem, Virginia 24153, United States
  • Highline Medical Oncology
    Burien, Washington 98166, United States
  • Puget Sound Cancer Center-Edmonds
    Edmonds, Washington 98026, United States
  • Puget Sound Cancer Center-Seattle
    Seattle, Washington 98133, United States
  • Cancer Care Northwest-South
    Spokane, Washington 99202, United States
  • Northwest Cancer Specialists-Vancouver
    Vancouver, Washington 98684, United States
  • Yakima Valley Mem Hosp/North Star Lodge
    Yakima, Washington 98902, United States
09

References and documents

Publications

  • Jones SE, Collea R, Paul D, Sedlacek S, Favret AM, Gore I Jr, Lindquist DL, Holmes FA, Allison MAK, Brooks BD, Portillo RM, Vukelja SJ, Steinberg MS, Stokoe C, Crockett MW, Wang Y, Asmar L, Robert NJ, O'Shaughnessy J. Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study. Lancet Oncol. 2013 Oct;14(11):1121-1128. doi: 10.1016/S1470-2045(13)70384-X. Epub 2013 Sep 3. PubMed 24007746 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2007
First posted
Jun 28, 2007
Start
Jun 2007
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Results first posted
Nov 3, 2016
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00493649
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jun 28, 2007
Start date
Jun 2007
Primary completion
Apr 2013
Completion
Apr 2013
Results posted
Nov 3, 2016
Last update
Nov 3, 2016

Study contacts

Stephen E Jones, MD
principal investigator · US Oncology Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Cyclophosphamide · Trastuzumab

Start the discussion